Favorable safety profile, in terms of liver abnormalities (abnormal AST or ALT in 3.2% of subjects), tumor growth (PitNET increase in 7.1% of patients), lipohypertrophy (1.2%), and decreased IGF1 levels (1.1%) (72).Peg-V improves glucose tolerance and insulin sensitivity in acromegalic patients with blood glucose alterations (71). This evidence concerns the gene IGF1 and neoplasm.